Logo image of MRNA

MODERNA INC (MRNA) Stock Fundamental Analysis

NASDAQ:MRNA - Nasdaq - US60770K1079 - Common Stock - Currency: USD

28.54  +0.72 (+2.59%)

After market: 28.79 +0.25 (+0.88%)

Fundamental Rating

3

Taking everything into account, MRNA scores 3 out of 10 in our fundamental rating. MRNA was compared to 566 industry peers in the Biotechnology industry. The financial health of MRNA is average, but there are quite some concerns on its profitability. MRNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MRNA has reported negative net income.
In the past year MRNA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: MRNA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MRNA reported negative operating cash flow in multiple years.
MRNA Yearly Net Income VS EBIT VS OCF VS FCFMRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

The Return On Assets of MRNA (-25.18%) is better than 72.08% of its industry peers.
Looking at the Return On Equity, with a value of -32.67%, MRNA is in the better half of the industry, outperforming 75.62% of the companies in the same industry.
Industry RankSector Rank
ROA -25.18%
ROE -32.67%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
MRNA Yearly ROA, ROE, ROICMRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

Looking at the Gross Margin, with a value of 68.70%, MRNA belongs to the top of the industry, outperforming 80.74% of the companies in the same industry.
In the last couple of years the Gross Margin of MRNA has declined.
MRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
MRNA Yearly Profit, Operating, Gross MarginsMRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

4

2. Health

2.1 Basic Checks

MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRNA has been increased compared to 1 year ago.
MRNA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MRNA has an improved debt to assets ratio.
MRNA Yearly Shares OutstandingMRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
MRNA Yearly Total Debt VS Total AssetsMRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

An Altman-Z score of 2.90 indicates that MRNA is not a great score, but indicates only limited risk for bankruptcy at the moment.
MRNA has a Altman-Z score of 2.90. This is in the better half of the industry: MRNA outperforms 75.80% of its industry peers.
MRNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
MRNA has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: MRNA outperforms 45.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.9
ROIC/WACCN/A
WACC9.92%
MRNA Yearly LT Debt VS Equity VS FCFMRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 3.67 indicates that MRNA has no problem at all paying its short term obligations.
MRNA has a Current ratio (3.67) which is in line with its industry peers.
A Quick Ratio of 3.62 indicates that MRNA has no problem at all paying its short term obligations.
With a Quick ratio value of 3.62, MRNA perfoms like the industry average, outperforming 45.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.62
MRNA Yearly Current Assets VS Current LiabilitesMRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

6

3. Growth

3.1 Past

MRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.22%, which is quite impressive.
MRNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -52.75%.
MRNA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 122.01% yearly.
EPS 1Y (TTM)25.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-629.09%
Revenue 1Y (TTM)-52.75%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-65.64%

3.2 Future

The Earnings Per Share is expected to grow by 18.49% on average over the next years. This is quite good.
The Revenue is expected to grow by 20.30% on average over the next years. This is a very strong growth
EPS Next Y-11.66%
EPS Next 2Y7.21%
EPS Next 3Y8.93%
EPS Next 5Y18.49%
Revenue Next Year-32.44%
Revenue Next 2Y-9.16%
Revenue Next 3Y0.51%
Revenue Next 5Y20.3%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MRNA Yearly Revenue VS EstimatesMRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
MRNA Yearly EPS VS EstimatesMRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNA Price Earnings VS Forward Price EarningsMRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNA Per share dataMRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.21%
EPS Next 3Y8.93%

More info and screens

0

5. Dividend

5.1 Amount

MRNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

NASDAQ:MRNA (4/30/2025, 8:22:58 PM)

After market: 28.79 +0.25 (+0.88%)

28.54

+0.72 (+2.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-14 2025-02-14/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners73.88%
Inst Owner Change0.54%
Ins Owners5.45%
Ins Owner Change0.05%
Market Cap11.03B
Analysts64.24
Price Target51.1 (79.05%)
Short Float %15.71%
Short Ratio5.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.64%
Min EPS beat(2)-6.26%
Max EPS beat(2)101.54%
EPS beat(4)3
Avg EPS beat(4)28.71%
Min EPS beat(4)-6.26%
Max EPS beat(4)101.54%
EPS beat(8)6
Avg EPS beat(8)1.03%
EPS beat(12)8
Avg EPS beat(12)2.8%
EPS beat(16)11
Avg EPS beat(16)3.24%
Revenue beat(2)2
Avg Revenue beat(2)23.24%
Min Revenue beat(2)0.45%
Max Revenue beat(2)46.04%
Revenue beat(4)4
Avg Revenue beat(4)48.29%
Min Revenue beat(4)0.45%
Max Revenue beat(4)78.74%
Revenue beat(8)8
Avg Revenue beat(8)36.49%
Revenue beat(12)10
Avg Revenue beat(12)27.34%
Revenue beat(16)12
Avg Revenue beat(16)19.08%
PT rev (1m)-8.08%
PT rev (3m)-32.01%
EPS NQ rev (1m)-1.17%
EPS NQ rev (3m)-3.55%
EPS NY rev (1m)-0.36%
EPS NY rev (3m)-13.03%
Revenue NQ rev (1m)-3.43%
Revenue NQ rev (3m)-59.37%
Revenue NY rev (1m)-0.85%
Revenue NY rev (3m)-20.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.41
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-9.28
EYN/A
EPS(NY)-10.36
Fwd EYN/A
FCF(TTM)-10.49
FCFYN/A
OCF(TTM)-7.77
OCFYN/A
SpS8.37
BVpS28.2
TBVpS27.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.18%
ROE -32.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.7%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 556.09%
Cap/Sales 32.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.67
Quick Ratio 3.62
Altman-Z 2.9
F-Score5
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-629.09%
EPS Next Y-11.66%
EPS Next 2Y7.21%
EPS Next 3Y8.93%
EPS Next 5Y18.49%
Revenue 1Y (TTM)-52.75%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-65.64%
Revenue Next Year-32.44%
Revenue Next 2Y-9.16%
Revenue Next 3Y0.51%
Revenue Next 5Y20.3%
EBIT growth 1Y11.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.67%
EBIT Next 3Y12.82%
EBIT Next 5Y18.31%
FCF growth 1Y-6.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.66%
OCF growth 3YN/A
OCF growth 5YN/A